Skip to main navigation Skip to search Skip to main content

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

  • David Mutch
  • , Athina Voulgari
  • , Xian Chen
  • , William H. Bradley
  • , Ana Oaknin
  • , José Alejandro Perez Fidalgo
  • , Fernando Galvez Montosa
  • , Antonio Casado Herraez
  • , Robert W. Holloway
  • , Matthew A. Powell
  • , Malgorzata Nowicka
  • , Gabriele Schaefer
  • , Mark Merchant
  • , Yibing Yan

Research output: Contribution to journal › Article › peer-review

5   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry